SRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. Dr. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. The average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. Because of confidentiality rules, the F.D.A. cannot release any information about the earlier pain studies that failed to sway regulators. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. Topol said. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. Scirex executives did not return repeated phone calls. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. One reviewer, Dr. Paul A. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. The Bextra episode is just one example of the changing face of drug research. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Omnicom says it has no control over Scirex. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help article speed new-drug applications, or N.D.A.'s, to the F.D.A. "Our goal," he said, "is to help ensure that all clinical studies and each patient accrued into a study can be assessed to support the N.D.A.
pga.org.nzIf your editor doesn't insist on a thorough technical review by outside readers and/or doesn't actively work to identify qualified reviewers, that's a sign that he or she isn't really concerned with the quality of your book. Different authors work with different text preparation tools (e.g., Word, FrameMaker, TeX, etc.), and you should discuss the format of your manuscript with your editor in advance. Later, when I began talking to other authors and hearing how awful their experiences had been, I realized that I'd won the editor lottery through sheer dumb luck. One problem we've encountered - and I suspect the same is true of every large publisher - is prospective authors calling the wrong office (a professional author calling a college office, for example) and getting misdirected. If you have any kind of concerns relating to where and how to use help guide, you can contact us at the page. Legal Office Supplies including Legal Stationery, Legal Index Tabs, Legal Exhibit Tabs and legal services Exhibit Dividers in several styles. This costs the publisher money, plus it almost always results in an awful index. Fundamentally, a publishing contract says that you give the publisher the right to publish your book, and in return, the publisher agrees to compensate you. "but car drivers would be surprised" says every traffic engineer and police officer I’ve spoken to about it.
At SEO Consulting Pros, we don’t just focus on web traffic. Concep offers firms easy to use template builders, web forms, web tracking, and more. Providers of behavioural advertising create audience segments based on web sites visited over a period of time with a particular browser. The silo can include related claims or break down aspects of particular claims - just be careful not to repeat information. Just smile and say hello to one of the more interesting aspects of the global economy. Nearly one and a half thousand ADA digital accessibility lawsuits were made against companies using accessibility widgets throughout 2025, and that number has steadily been increasing over previous years. If you’re not using email marketing for your legal practice, you are losing clients and opportunities every single day-and you don’t even know it. Don’t Expect Them to Bounce Back Soon. If you don't fulfill your end of the bargain by delivering a publishable book on time, you're contract-bound to pay the advance back (otherwise it'd be a grant - see below), though I've heard that enforcement of this payback provision can be pretty lax. One thing they do - or at least should do - is publicize your book to potential buyers in advance, thus leading to that sweetest of publishing delicacies, advance sales.
1
Promoting Legal Professionals Modifications: 5 Actionable Ideas
Layla Troedel edited this page 2026-10-09 15:55:58 +08:00